<p>在今天发布的一份报告中，Stifel Nicolaus 的 Stephen Willey 对 Pyxis Oncology 维持了买入评级，目标价为 9.00 美元。</p>
<h3>享受 TipRanks Premium 50% 折扣，信心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的位置</li>
</ul>
<p>根据 TipRanks，Willey 是一位四星分析师，平均回报率为 7.6%，成功率为 41.89%。Willey 关注医疗保健领域，重点关注 Zymeworks、Nurix Therapeutics 和 Pyxis Oncology 等股票。</p>
<p>除了 Stifel Nicolaus，Pyxis Oncology 还在今天的报告中获得了 LifeSci Capital 的 Sam Slutsky 的买入评级。然而，William Blair 昨天重申了对 Pyxis Oncology (NASDAQ: PYXS) 的持有评级。</p>

PYXS

<p>Stifel Nicolaus 分析师 Stephen Willey 对 Pyxis Oncology 维持买入评级，目标价为 9.00 美元。Willey 是 TipRanks 上的四星分析师，专注于医疗保健领域。LifeSci Capital 的 Sam Slutsky 也发布了买入评级，而 William Blair 则重申了对 Pyxis Oncology 的持有评级</p>

<p>In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Pyxis Oncology, with a price target of $9.00.</p>
<div class="lb-trans"><p>在今天发布的一份报告中，Stifel Nicolaus 的 Stephen Willey 对 Pyxis Oncology 维持了买入评级，目标价为 9.00 美元。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks Premium 50% 折扣，信心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的位置</li>
</ul>
</div><p>According to TipRanks, Willey is a 4-star analyst with an average return of 7.6% and a 41.89% success rate. Willey covers the Healthcare sector, focusing on stocks such as Zymeworks, Nurix Therapeutics, and Pyxis Oncology.</p>
<div class="lb-trans"><p>根据 TipRanks，Willey 是一位四星分析师，平均回报率为 7.6%，成功率为 41.89%。Willey 关注医疗保健领域，重点关注 Zymeworks、Nurix Therapeutics 和 Pyxis Oncology 等股票。</p>
</div><p>In addition to Stifel Nicolaus, Pyxis Oncology also received a Buy from LifeSci Capital’s Sam Slutsky in a report issued today. However, yesterday, William Blair reiterated a Hold rating on Pyxis Oncology (NASDAQ: PYXS).</p>
<div class="lb-trans"><p>除了 Stifel Nicolaus，Pyxis Oncology 还在今天的报告中获得了 LifeSci Capital 的 Sam Slutsky 的买入评级。然而，William Blair 昨天重申了对 Pyxis Oncology (NASDAQ: PYXS) 的持有评级。</p>
</div>

Stifel Nicolaus 维持对 Pyxis Oncology（PYXS）的买入评级